001     281368
005     20251008102406.0
024 7 _ |a 10.1186/s13023-025-04009-3
|2 doi
024 7 _ |a pmid:40922023
|2 pmid
024 7 _ |a pmc:PMC12418672
|2 pmc
037 _ _ |a DZNE-2025-01115
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wurster, Claudia D
|b 0
245 _ _ |a Respiratory function in 192 adult patients with spinal muscular atrophy (SMA) treated with nusinersen - a multicenter observational study.
260 _ _ |a London
|c 2025
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1759836491_17319
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Natural history data show that respiratory function is impaired in SMA patients. Observational studies have shown stabilization of respiratory function in adult SMA patients treated with nusinersen. However, long-term studies investigating the effect of nusinersen on respiratory function in adult SMA patients are rare.We examined respiratory function using forced vital capacity of predicted normal (FVC%), FVC in liters, capacity per second (FEV1) and peak expiratory flow (PEF) in 192 adult SMA patients treated with nusinersen for a median of 3.2 years (IQR: 2.1–4.0, range: 0.2–5.2). Changes in spirometric parameters were analyzed using individual linear regression models separate in each patient to estimate the slope. Additionally, three multivariable models were performed to assess the effect of age, sex, treatment duration, baseline FVC% and each one of the variables of interest (1) SMA type, (2) ambulation status, (3) spondylodesis on follow-up FVC%. Associations between respiratory parameters and motor function (HFMSE) were investigated via Scatter plots and Spearman’s rank correlation.Spirometric parameters remained stable during treatment (median annual rate of change of FVC% 0.17% (p = 0.40), FVC in liters -0.002 (p = 0.59), FEV1 -0.014 l (p = 0.06) and PEF 0.025 l/s (p = 0.65)). In all multivariable models, age, sex, treatment duration, SMA type, ambulation status, and spondylodesis showed no significant association with follow-up FVC%. No significant correlations were observed between respiratory and motor function.Respiratory parameters remained stable during treatment with nusinersen in adult SMA patients over several years.Not applicable.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Adult patients
|2 Other
650 _ 7 |a Forced vital capacity (FVC)
|2 Other
650 _ 7 |a Nusinersen
|2 Other
650 _ 7 |a Respiratory function
|2 Other
650 _ 7 |a Spinal muscular atrophy (SMA)
|2 Other
700 1 _ |a Stolte, Benjamin
|b 1
700 1 _ |a Kessler, Tobias
|b 2
700 1 _ |a Freigang, Maren
|b 3
700 1 _ |a Bjelica, Bogdan
|b 4
700 1 _ |a Ilse, Benjamin
|b 5
700 1 _ |a Koch, Jan C
|b 6
700 1 _ |a Cordts, Isabell
|b 7
700 1 _ |a Mensch, Alexander
|b 8
700 1 _ |a Zeller, Daniel
|b 9
700 1 _ |a Uzelac, Zeljko
|b 10
700 1 _ |a Sam, Georges
|b 11
700 1 _ |a Lapp, Hanna Sophie
|b 12
700 1 _ |a Wohnrade, Camilla
|b 13
700 1 _ |a Rödiger, Annekathrin
|b 14
700 1 _ |a Muhandes, Mohamad Tareq
|b 15
700 1 _ |a Schneider, Ilka
|b 16
700 1 _ |a Bellut, Julia
|b 17
700 1 _ |a Nentwich, Julia
|b 18
700 1 _ |a Dorst, Johannes
|0 P:(DE-2719)9001951
|b 19
|u dzne
700 1 _ |a Schuster, Joachim
|0 P:(DE-2719)9002279
|b 20
|u dzne
700 1 _ |a Schreiber-Katz, Olivia
|b 21
700 1 _ |a Osmanovic, Alma
|b 22
700 1 _ |a Totzeck, Andreas
|b 23
700 1 _ |a Thimm, Andreas
|b 24
700 1 _ |a Steinbach, Robert
|b 25
700 1 _ |a Grosskreutz, Julian
|b 26
700 1 _ |a Kleinschnitz, Christoph
|b 27
700 1 _ |a Ludolph, Albert C
|0 P:(DE-2719)2812633
|b 28
|u dzne
700 1 _ |a Deschauer, Marcus
|b 29
700 1 _ |a Kirschner, Janbernd
|b 30
700 1 _ |a Dreyhaupt, Jens
|b 31
700 1 _ |a Wollinsky, Kurt
|b 32
700 1 _ |a Petri, Susanne
|b 33
700 1 _ |a Weiler, Markus
|b 34
700 1 _ |a Hagenacker, Tim
|b 35
700 1 _ |a Günther, René
|0 P:(DE-2719)2811849
|b 36
|e Last author
|u dzne
773 _ _ |a 10.1186/s13023-025-04009-3
|g Vol. 20, no. 1, p. 476
|0 PERI:(DE-600)2225857-7
|n 1
|p 476
|t Orphanet journal of rare diseases
|v 20
|y 2025
|x 1750-1172
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/281368/files/DZNE-2025-01115.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/281368/files/DZNE-2025-01115.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:281368
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)9001951
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)9002279
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)2812633
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 36
|6 P:(DE-2719)2811849
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ORPHANET J RARE DIS : 2022
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:44:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:44:07Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-11
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1120
|2 StatID
|b BIOSIS Reviews Reports And Meetings
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-11
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 0
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1710012
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21